Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (1): 117-118.DOI: 10.3969/j.issn.1673-8640.2021.01.025
Received:2019-10-31
Online:2021-01-30
Published:2021-02-05
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.01.025
| [1] | 吴仪,郑筱更. 药品不良反应报告和监测管理办法[J]. 中国药事,2004,23(4):203-205. |
| [2] | 王利军,吴洁,崔示德,等. 血小板生成素与感染相关性反应性血小板增多关系的研究[J]. 中国医师进修杂志,2012,35(25):24-26. |
| [3] | PALANDRI F,CATANI L,TESTONI N,et al.Long-term follow-up of 386 consecutive patients with essential thrombocythemia:safety of cytoreductive therapy[J]. Am J Hematol,2009,84(4):215-220. |
| [4] | 陈沈珏,李昕,刘丽华,等. 药物致继发性血小板增多症文献分析[J]. 中国药师,2017,20(9):1633-1635. |
| [5] | NORRBY S R,NEWELL P A,FAULKNER K L,et al.Safety profile of meropenem:international clinical experience based on the first 3 125 patients treated with meropenem[J]. J Antimicrob Chemother,1995,36(Suppl A):207-223. |
| [6] | WANG X,ZHANG X,ZONG Z,et al.Biapenem versus meropenem in the treatment of bacterial infections:a multicenter,randomized,controlled clinical trial[J]. Indian J Med Res,2013,138(6):995-1002. |
| [7] | LIN Y F,YANG C H,SINDY H,et al.Severe cutaneous adverse reactions related to systemic antibiotics[J]. Clin Infect Dis,2014,58(10):1377-1385. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
